About this Journal Submit a Manuscript Table of Contents
ISRN Otolaryngology
Volume 2012 (2012), Article ID 797619, 12 pages
http://dx.doi.org/10.5402/2012/797619
Review Article

A New Strategy to Find Targets for Anticancer Therapy: Chemokine CXCL14/BRAK Is a Multifunctional Tumor Suppressor for Head and Neck Squamous Cell Carcinoma

Oral Health Science Research Center, Kanagawa Dental College, 82 Inaoka-cho, Yokosuka 238-8580, Japan

Received 29 August 2012; Accepted 14 September 2012

Academic Editors: S. L. Halum and S. C. Winter

Copyright © 2012 Ryu-Ichiro Hata. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. S. Ozawa, Y. Kato, R. Komori, Y. Maehata, E. Kubota, and R. I. Hata, “BRAK/CXCL14 expression suppresses tumor growth in vivo in human oral carcinoma cells,” Biochemical and Biophysical Research Communications, vol. 348, no. 2, pp. 406–412, 2006. View at Publisher · View at Google Scholar · View at Scopus
  2. S. Ozawa, Y. Kato, E. Kubota, and R. I. Hata, “BRAK/CXCL14 expression in oral carcinoma cells completely suppresses tumor cell xenografts in SCID mouse,” Biomedical Research, vol. 30, no. 5, pp. 315–318, 2009. View at Publisher · View at Google Scholar · View at Scopus
  3. S. Ozawa, Y. Kato, S. Ito et al., “Restoration of BRAK/CXCl14 gene expression by gefitinib is associated with antitumor efficacy of the drug in head and neck squamous cell carcinoma,” Cancer Science, vol. 100, no. 11, pp. 2202–2209, 2009. View at Publisher · View at Google Scholar · View at Scopus
  4. K. Sato, S. Ozawa, K. Izukuri, Y. Kato, and R. I. Hata, “Expression of tumour-suppressing chemokine BRAK/CXCL14 reduces cell migration rate of HSC-3 tongue carcinoma cells and stimulates attachment to collagen and formation of elongated focal adhesions in vitro,” Cell Biology International, vol. 34, no. 5, pp. 513–522, 2010. View at Publisher · View at Google Scholar · View at Scopus
  5. S. Ito, S. Ozawa, T. Ikoma, N. Yajima, T. Kiyono, and R. I. Hata, “Expression of a chemokine BRAK/CXCL14 in oral floor carcinoma cells reduces the settlement rate of the cells and suppresses their proliferation in vivo,” Biomedical Research, vol. 31, no. 3, pp. 199–206, 2010. View at Publisher · View at Google Scholar · View at Scopus
  6. K. Izukuri, K. Suzuki, N. Yajima et al., “Chemokine CXCL14/BRAK transgenic mice suppress growth of carcinoma cell xenografts,” Transgenic Research, vol. 19, no. 6, pp. 1109–1117, 2010. View at Publisher · View at Google Scholar · View at Scopus
  7. K. D. Hunter, E. K. Parkinson, and P. R. Harrison, “Profiling early head and neck cancer,” Nature Reviews Cancer, vol. 5, no. 2, pp. 127–135, 2005. View at Publisher · View at Google Scholar · View at Scopus
  8. C. R. Leemans, B. J. M. Braakhuis, and R. H. Brakenhoff, “The molecular biology of head and neck cancer,” Nature Reviews Cancer, vol. 11, no. 1, pp. 9–22, 2011. View at Publisher · View at Google Scholar · View at Scopus
  9. D. Hanahan and R. A. Weinberg, “The hallmarks of cancer,” Cell, vol. 100, no. 1, pp. 57–70, 2000. View at Scopus
  10. B. Vogelstein, E. R. Fearon, S. R. Hamilton et al., “Genetic alterations during colorectal-tumor development,” New England Journal of Medicine, vol. 319, no. 9, pp. 525–532, 1988. View at Scopus
  11. D. Sidransky, “Emerging molecular markers of cancer,” Nature Reviews Cancer, vol. 2, no. 3, pp. 210–219, 2002. View at Scopus
  12. R. J. Akhurst, “TGF-β antagonists: why suppress a tumor suppressor?” Journal of Clinical Investigation, vol. 109, no. 12, pp. 1533–1536, 2002. View at Publisher · View at Google Scholar · View at Scopus
  13. P. Benatti, V. Basile, D. Merico, L. I. Fantoni, E. Tagliafico, and C. Imbriano, “A balance between NF-Y and p53 governs the pro- and anti-apoptotic transcriptional response,” Nucleic Acids Research, vol. 36, no. 5, pp. 1415–1428, 2008. View at Publisher · View at Google Scholar · View at Scopus
  14. J. M. Roodhart, M. H. Langenberg, E. Witteveen, and E. E. Voest, “The molecular basis of class side effects due to treatment with inhibitors of the VEGF/VEGFR pathway,” Current Clinical Pharmacology, vol. 3, no. 2, pp. 132–143, 2008. View at Publisher · View at Google Scholar · View at Scopus
  15. P. S. Steeg and D. Theodorescu, “Metastasis: a therapeutic target for cancer,” Nature Clinical Practice Oncology, vol. 5, no. 4, pp. 206–219, 2008. View at Publisher · View at Google Scholar · View at Scopus
  16. T. Yoshimura, K. Matsushima, S. Tanaka et al., “Purification of a human monocyte-derived neutrophil chemotactic factor that has peptide sequence similarity to other host defense cytokines.,” Proceedings of the National Academy of Sciences of the United States of America, vol. 84, no. 24, pp. 9233–9237, 1987. View at Scopus
  17. T. Kakinuma and S. T. Hwang, “Chemokines, chemokine receptors, and cancer metastasis,” Journal of Leukocyte Biology, vol. 79, no. 4, pp. 639–651, 2006. View at Publisher · View at Google Scholar · View at Scopus
  18. D. Raman, P. J. Baugher, Y. M. Thu, and A. Richmond, “Role of chemokines in tumor growth,” Cancer Letters, vol. 256, no. 2, pp. 137–165, 2007. View at Publisher · View at Google Scholar · View at Scopus
  19. D. Raman, P. J. Baugher, Y. M. Thu, and A. Richmond, “Role of Chemokines in Tumor Growth,” Cancer Letters, vol. 256, no. 2, pp. 137–165, 2007.
  20. A. Zlotnik, O. Yoshie, and H. Nomiyama, “The chemokine and chemokine receptor superfamilies and their molecular evolution,” Genome Biology, vol. 7, no. 12, article 243, 2006. View at Publisher · View at Google Scholar · View at Scopus
  21. S. Meuter and B. Moser, “Constitutive expression of CXCL14 in healthy human and murine epithelial tissues,” Cytokine, vol. 44, no. 2, pp. 248–255, 2008. View at Publisher · View at Google Scholar · View at Scopus
  22. I. Kurth, K. Willimann, P. Schaerli, T. Hunziker, I. Clark-Lewis, and B. Moser, “Monocyte selectivity and tissue localization suggests a role for breast and kidney-expressed chemokine (BRAK) in macrophage development,” Journal of Experimental Medicine, vol. 194, no. 6, pp. 855–861, 2001. View at Publisher · View at Google Scholar · View at Scopus
  23. P. Schaerli, K. Willimann, L. M. Ebert, A. Walz, and B. Moser, “Cutaneous CXCL14 targets blood precursors to epidermal niches for langerhans cell differentiation,” Immunity, vol. 23, no. 3, pp. 331–342, 2005. View at Publisher · View at Google Scholar · View at Scopus
  24. T. Starnes, K. K. Rasila, M. J. Robertson et al., “The chemokine CXCL14 (BRAK) stimulates activated NK cell migration: implications for the downregulation of CXCL14 in malignancy,” Experimental Hematology, vol. 34, no. 8, pp. 1101–1105, 2006. View at Publisher · View at Google Scholar · View at Scopus
  25. N. Nara, Y. Nakayama, S. Okamoto et al., “Disruption of CXC motif chemokine ligand-14 in mice ameliorates obesity-induced insulin resistance,” Journal of Biological Chemistry, vol. 282, no. 42, pp. 30794–30803, 2007. View at Publisher · View at Google Scholar · View at Scopus
  26. T. D. Shellenberger, M. Wang, M. Gujrati et al., “BRAK/CXCL14 is a potent inhibitor of angiogenesis and a chemotactic factor for immature dendritic cells,” Cancer Research, vol. 64, no. 22, pp. 8262–8270, 2004. View at Publisher · View at Google Scholar · View at Scopus
  27. C. A. O'Brien, A. Pollett, S. Gallinger, and J. E. Dick, “A human colon cancer cell capable of initiating tumour growth in immunodeficient mice,” Nature, vol. 445, no. 7123, pp. 106–110, 2007. View at Publisher · View at Google Scholar · View at Scopus
  28. L. Ricci-Vitiani, D. G. Lombardi, E. Pilozzi et al., “Identification and expansion of human colon-cancer-initiating cells,” Nature, vol. 445, no. 7123, pp. 111–115, 2007. View at Publisher · View at Google Scholar · View at Scopus
  29. A. Castellanos, C. Vicente-Dueñas, E. Campos-Sánchez et al., “Cancer as a reprogramming-like disease: implications in tumor development and treatment,” Seminars in Cancer Biology, vol. 20, no. 2, pp. 93–97, 2010. View at Publisher · View at Google Scholar · View at Scopus
  30. S. R. Schwarze, J. Luo, W. B. Isaacs, and D. F. Jarrard, “Modulation of CXCL14 (BRAK) expression in prostate cancer,” Prostate, vol. 64, no. 1, pp. 67–74, 2005. View at Publisher · View at Google Scholar · View at Scopus
  31. M. Allinen, R. Beroukhim, L. Cai et al., “Molecular characterization of the tumor microenvironment in breast cancer,” Cancer Cell, vol. 6, no. 1, pp. 17–32, 2004. View at Publisher · View at Google Scholar · View at Scopus
  32. H. Pelicano, W. Lu, Y. Zhou et al., “Mitochondrial dysfunction and reactive oxygen species imbalance promote breast cancer cell motility through a CXCL14-mediated mechanism,” Cancer Research, vol. 69, no. 6, pp. 2375–2383, 2009. View at Publisher · View at Google Scholar · View at Scopus
  33. M. N. Wente, C. Mayer, M. M. Gaida et al., “CXCL14 expression and potential function in pancreatic cancer,” Cancer Letters, vol. 259, no. 2, pp. 209–217, 2008. View at Publisher · View at Google Scholar · View at Scopus
  34. S. Ozawa, S. Ito, Y. Kato, E. Kubota, and R. I. Hata, “Human p38δ MAP kinase mediates UV irradiation induced up-regulation of the gene expression of chemokine BRAK/CXCL14,” Biochemical and Biophysical Research Communications, vol. 396, no. 4, pp. 1060–1064, 2010. View at Publisher · View at Google Scholar · View at Scopus
  35. Y. Maehata, S. Ozawa, K. Kobayashi et al., “Reactive oxygen species (ROS) reduce the expression of BRAK/CXCL14 in human head and neck squamous cell carcinoma cells,” Free Radical Research, vol. 44, no. 8, pp. 913–924, 2010. View at Publisher · View at Google Scholar · View at Scopus
  36. R. Komori, S. Ozawa, Y. Kato, H. Shinji, S. Kimoto, and R. I. Hata, “Functional characterization of proximal promoter of gene for human BRAK/CXCL14, a tumor-suppressing chemokine,” Biomedical Research, vol. 31, no. 2, pp. 123–131, 2010. View at Publisher · View at Google Scholar · View at Scopus
  37. R. Hata, “Regulation of CXCL14/BRAK, a tumor-suppressing chemokine, by MAP kinase subtype-specific crosstalk,” Seikagaku, vol. 83, no. 8, pp. 731–736, 2011.
  38. M. Pàez-Ribes, E. Allen, J. Hudock et al., “Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis,” Cancer Cell, vol. 15, no. 3, pp. 220–231, 2009. View at Publisher · View at Google Scholar · View at Scopus
  39. J. M. L. Ebos, C. R. Lee, W. Cruz-Munoz, G. A. Bjarnason, J. G. Christensen, and R. S. Kerbel, “Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis,” Cancer Cell, vol. 15, no. 3, pp. 232–239, 2009. View at Publisher · View at Google Scholar · View at Scopus
  40. K. Izukuri, S. Ito, N. Nozaki et al., “Determination of serum BRAK/CXCL14 levels in healthy volunteers,” Laboratory Medicine, vol. 41, no. 8, pp. 478–482, 2010. View at Publisher · View at Google Scholar · View at Scopus